Home › Premarket Biotech Digest: Breast Cancer Therapies, Anavex's Milestone, Praluent EU Approval
 

Keywords :   


Premarket Biotech Digest: Breast Cancer Therapies, Anavex's Milestone, Praluent EU Approval

2015-09-29 16:11:27| Biotech - Topix.net

Targeted therapies in breast cancer are the latest developments in this area of therapeutics. Although these therapies sometimes cause serious side effects, for example, damage to heart muscles in some HER2 inhibitors, they offer a non-surgical option for treating breast cancer.

Tags: approval cancer breast digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11()PC-88015\"2D
23.11180&100m
23.11kenG
23.11ps3 CECH-4300C HDMI500
23.11 UNDERTALE PIANO SCORE
23.11MM6 BM11-SEC3 LC
23.11
23.11Blu-ray
More »